Phase II study of the combination of oral vinorelbine (NVBo), capecitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): Recent analysis of the results with a median follow-up of 44 months.
2010 ◽
Vol 28
(15_suppl)
◽
pp. 1077-1077
◽
Keyword(s):
Phase Ii
◽